Health data interoperability remains one of Europe’s most complex technological frontiers. A patient consults a general practitioner, who sends a request to a cardiologist, who orders tests from a laboratory, who communicates results to a hospital. Each uses its own systems, its own formats. Information flows only on paper or email, slowly and incompletely. The European Health Data Space (EHDS) aims to change this reality.
Current fragmentation
Today, Europe has twenty-seven distinct health systems, each with its own data governance. France uses different standards than Germany or Switzerland. English hospitals operate independently of medical practices. This fragmentation reflects historical system autonomy but carries a cost: patients repeat their medical history to each new provider; professionals recreate already-collected data; clinical research slows due to access barriers.
Europe’s health interoperability market represents approximately 2.1 billion dollars in 2025, with projected annual growth of 14 percent. Public and private investment follows this dynamic, yet progress remains uneven: some countries advance, others stagnate.
The EHDS directive
The European Commission launched the European Health Data Space directive in 2022. The objective is ambitious: enable patients to access their electronic health record, allow all relevant professionals to consult essential information, and let researchers access anonymised data for research. The directive must take effect in 2025.
Concretely, it requires technical interoperability around open standards: HL7 FHIR for structured data exchange, SNOMED CT for medical term coding. It also imposes governance: who can access data? What consents are required? How do data protection rights coexist with sharing?
Technical obstacles
European health systems rest on legacy architectures, built progressively. A French hospital may be ten years behind HL7 FHIR standards. A medical practice in Belgium operates with proprietary software lacking APIs. Modernising this foundation is technically complex and financially costly.
Software vendors (CompuGroup Medical, CGM, Medixp) work toward system adaptation at uneven paces. A small practice cannot wait five years for complete migration; it must continue serving patients tomorrow. This tension between necessary change and operational urgency slows adoption.
Regulatory obstacles
Regulation further complicates matters. Which jurisdiction governs transnational health data? A German patient consulting a French doctor, then accessing records in Switzerland: which GDPR applies? How do national health authorities maintain control over data leaving their territory?
These questions remain far from resolved. Some countries defend sovereignty logic: health data must not leave the territory. Others, notably the Baltics and Scandinavia, have already adopted more open vision. Europe-wide harmonisation will remain slow.
Concrete advances
A few initiatives show progress is possible. Baltic states (Estonia, Latvia, Lithuania) structured interoperability a decade ago. Sweden created a shared national repository. The Netherlands pilot cross-border exchange projects. These successes rest on strong political will and populations accepting data sharing.
Measurable benefits exist: reduced redundant testing, improved detection of drug interactions, better clinical outcomes. A 2024 study reports interoperability reduces medical errors by 12 to 18 percent in advanced systems. This justifies investment, but the journey remains long.